Interleukin-33 (IL-33) is a member of the IL-1 superfamily and activates group 2 innate lymphoid cells (ILC2), mast cells, and their progenitors. Studies indicate that ILCs, which secrete copious amounts of IL-5 and IL-13 in response to IL-33, play critical roles in directing the development of type-2 immunity and allergic inflammation. In this issue of *Cellular and Molecular Gastroenterology and Hepatology*, Buzzelli et al[@bib1] provide novel insights into the role that IL-33 exerts on the gastric immune response to infection with the pathogen *Helicobacter pylori*.

Chronic *H. pylori*-induced gastritis is mediated by a variety of constituents, including gastric epithelial cells, neutrophils, macrophages, and dendritic cells that lead to a T~H~1-biased lymphocyte response. One microbial determinant that augments gastric cancer risk is the *cag* pathogenicity island, and *cag*^*+*^ strains significantly increase the risk for severe gastritis, atrophic gastritis, and cancer compared with strains lacking the *cag* island.[@bib2] Another *H. pylori* factor, neutrophil-activating protein, promotes neutrophil recruitment, contributes to T~H~1 polarization by stimulating both IL-12 and IL-23, and influences the production of T~H~1 cells, resulting in increased production of interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and cytolytic activity of T helper (T~H~) cells.[@bib3] *H. pylori* also activates macrophages, resulting in the production of IL-1 and TNF-α,[@bib4] in turn, promoting a T~H~1-directed response. Dendritic cells (DCs) represent a critical bridge between the innate and adaptive immune responses. In response to *H. pylori*, DCs drive T~H~1-effector responses, leading to production of TNF-α, IFN-γ, and IL-2.[@bib5] Consistent with a T~H~1-type cytokine response, gastric lymphocyte populations from *H. pylori*-infected patients harbor IFN-γ-producing T cells; after stimulation, these cells produce abundant levels of the T~H~1 cytokines IFN-γ and IL-2 and low levels of the T~H~2 cytokines IL-4 and IL-5.[@bib6] Collectively, the host immune response to *H. pylori* is predominantly a T~H~1-type response, which leads to the development of a chronic inflammatory infiltrate that fails to eliminate this pathogen.

Buzzelli et al demonstrate that IL-33 expression is *increased* in response to acute *H. pylori* infection but is reciprocally *suppressed* during chronic *H. pylori* infection in mice and humans, which contributes to the dominant T~H~1-polarized phenotype observed within infected gastric mucosa. To define the gastric response to IL-33 per se, mice were treated with recombinant IL-33. Chronic IL-33 administration led to increased gastric inflammation and the development of atrophy and metaplasia. Using flow cytometry to characterize immune cell populations in response to IL-33, the authors demonstrated no differences in the number of lymphocytes, but noted a significant expansion of myeloid-derived immunocytes, including macrophages, myeloid-derived suppressor cells, neutrophils, and DCs. IL-33 has been previously shown to activate ILC2, T~H~2 immunocytes, and a T~H~2 cytokine response, and chronic IL-33 administration results in increased expression of ILC2 markers and the T~H~2 cytokine IL-4 in the stomach. Conversely, concomitant infection with *H. pylori* suppressed IL-33 production, which corresponded to decreased expression of ILC2 markers.

This study provides novel findings regarding the role of IL-33 in gastric immune responses, but more importantly, it has established a framework for future studies in this field. The authors demonstrate that IL-33 expression is increased with increasing bacterial abundance and diversity. This is noteworthy when viewed within the context of *H. pylori* infection, as infection with *H. pylori* leads to a decrease in the diversity of gastric microbial communities.[@bib7] Thus, the diversity of the microbiome, in conjunction with a bacterial pathogen, may contribute to the complex regulation of IL-33.

The authors also demonstrate that expression of IL-33 in the stomach is partially regulated by TFF2. *H. pylori* up-regulates TFF2 in gastric tissue in both humans and mice, and loss of TFF2 expression in vivo results in a significant increase in *H. pylori*-induced IFN-γ production, gastric inflammation, atrophy, metaplasia, and dysplasia,[@bib8] which may be related to TFF2-mediated regulation of IL-33. What could account for the ability of IL-33 alone to induce gastric atrophy and metaplasia, lesions that are also induced by *H. pylori?* Based on the dramatic and divergent expression pattern of IL-33 in response to *H. pylori*, follow-up studies should focus on additional host factors that regulate IL-33 expression in the stomach.

In terms of microbial determinants, the authors demonstrate that the *H. pylori* strain SS1 induces IL-33 during acute infection but suppresses IL-33 during chronic infection in mice. Because SS1 lacks a functional *cag* type IV secretion system, these data suggest that *H. pylori* strains that harbor a functional *cag* secretion system could differentially regulate IL-33 expression, which can be easily tested. Future studies that investigate mechanisms by which *H. pylori* temporally activates and suppresses IL-33 expression will be crucial in understanding immune responses to this gastric pathogen.
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